FBXW7-AS1 and primary peritoneal carcinoma: Nevertheless, the work presented here comprehensively support DEspR as an important and clinically relevant therapeutic target in PPC, with DEspR-inhibition providing a promising therapeutic approach for patients with pancreatic peritoneal carcinomatosis.